Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
The purpose of this trial is to study the efficacy and safety of the triplet combination of TLK286, carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
DRUG: TLK286|DRUG: carboplatin|DRUG: paclitaxel
Study Objectives, 1. To determine the MTD of patients treated with the triplet combination of TLK286, paclitaxel and carboplatin
2. To determine the safety of patients treated with the triplet combination of TLK286, paclitaxel and carboplatin
3. To determine the objective response rate (ORR) of patients treated with the triplet combination of TLK286, paclitaxel and carboplatin, Every 6 Weeks
The purpose of this trial is to study the efficacy and safety of the triplet combination of TLK286, carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.